🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Sonoma Pharmaceuticals, Inc. SNOA PHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · United States
https://sonomapharma.com
Company Profile ↓
$1.33
-56.39% 1Y
Mkt Cap$6.37M
P/E-1.09
P/B0.74
52W High$5.35
52W Low$1.01
Book Value$1.72
EPS (TTM)$-1.22

Company Overview

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.11.

Recent Developments

  • Mar 2026 Revenue of $19.53M (+36.7% YoY); net profit $-3.17M.
  • Trailing 12 Months Year-on-year growth — revenue +59.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 5.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:5.08%
1 Year:59.60%

Stock Price Performance

1 Year:-56.39%
6 Months:-46.80%
3 Months:+22.02%
1 Month:-7.64%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 7% of range
$1.01 $5.35
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)54.74 · Neutral
Price Performance
1M-7.64%
3M+22.02%
6M-46.80%
1Y-56.39%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Trading 75.1% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-1.09
Industry PE
24.83
Forward P/E
-2.38
PEG Ratio
1.08
Book Value
$1.72
Price to Book
0.74
P/S
0.28
EV/EBITDA
-1.20
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
5.08%
Profit 5Y
-
Revenue (YoY)
59.60%
Earnings (YoY)
-

Profitability & Returns

ROCE
-26.96%
ROE
-42.52%
ROA
-5.37%
Profit Margin
-10.33%
Op Margin
-0.62%
Gross Margin
38.90%
EPS (Latest Qtr)
$-0.48
EPS (TTM)
$-1.22

Balance Sheet & Liquidity

Debt/Equity
0.11
Quick Ratio
1.56
Current Ratio
2.99
Debt
$739.00K
Total Assets
$13.96M
Current Assets
$12.10M
Working Capital
$7.27M

Ownership

Promoter Holding
0.42%
Chg in Prom Hold
-
FII / Inst Holding
2.31%
Chg in FII Hold
0.92%

Financial Snapshot

Enterprise Value
$6.37M
Total Revenue (TTM)
$21.92M
EBITDA
$-1.27M
Free Cash Flow
$-1.47M
Operating Cash Flow
$-2.57M
Shares Outstanding
4.79M
Gross Margin
38.90%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SNOA Sonoma Pharmaceuticals, Inc. PHARMA 1.33 -1.09 $6.37M 0.00% -26.96% -42.52% 5.08% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2013Dec 2013Jun 2014Sep 2014Dec 2014Jun 2015Sep 2015Dec 2015Jun 2016Sep 2016Dec 2016Jun 2017Sep 2017Dec 2017Jun 2018Sep 2018Dec 2018Jun 2019Sep 2019Dec 2019Jun 2020Sep 2020Dec 2020Jun 2021Sep 2021Dec 2021Jun 2022Sep 2022Dec 2022Jun 2023Sep 2023Dec 2023Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -----------------4.38M4.73M4.39M5.77M5.77M4.94M3.68M3.74M2.90M3.98M3.33M2.94M3.43M2.73M3.14M3.39M3.58M-3.75M4.01M5.60M4.35M5.56M
Cost of Revenue -----------------------------------2.23M2.55M3.48M2.70M3.38M
Gross Profit 2.71M2.11M1.91M1.73M1.66M1.87M2.09M455.00K981.00K1.04M1.71M1.76M1.85M2.37M1.73M2.43M2.85M2.18M2.17M2.00M2.25M2.50M2.00M1.45M1.24M1.20M1.65M1.54M831.00K1.20M990.00K1.46M1.31M1.36M-1.53M1.46M2.12M1.65M2.18M
Operating Expenses -----------------------------------2.18M2.56M2.46M2.33M2.53M
Operating Income -1.27M-1.55M-1.51M-1.54M-1.95M-2.31M-1.86M-4.19M-3.51M-2.99M-3.56M-3.38M-2.86M-3.20M-3.55M-2.65M-2.35M-1.91M-1.29M-1.11M-665.00K169.00K-138.00K-904.00K-964.00K-958.00K-855.00K-731.00K-1.83M-1.24M-1.21M-844.00K-1.17M-850.00K--656.00K-1.09M-337.00K-678.00K-351.00K
EBITDA ------------------------------------625.00K-1.06M-301.00K-644.00K-318.00K
Interest Expense ----------------------------------------
Pretax Income ------------------------------------528.00K-1.24M-731.00K-949.00K-497.00K
Tax Provision -----------------------------------248.00K-1.00K-197.00K-130.00K84.00K
Net Income -1.40M-611.00K-70.00K-718.00K-5.91M-2.34M-1.76M-3.15M-2.57M-1.95M16.23M-3.51M-2.87M-3.19M-3.46M-2.82M-2.30M715.00K-1.20M-1.08M240.00K120.00K-650.00K-1.10M-100.00K-944.00K-887.00K-1.02M-1.94M-1.42M-1.48M-866.00K-1.14M-610.00K--776.00K-1.24M-534.00K-819.00K-581.00K
Diluted EPS --------0.96--3.84---0.73-4.99--0.54-0.92-0.130.06-0.32-0.52-0.04-0.31-0.29-0.33-0.62-0.29-5.75-1.59-1.34-0.59-0.63--0.76-0.32-0.48-
R&D Expense 883.00K775.00K439.00K353.00K367.00K467.00K412.00K486.00K360.00K379.00K487.00K382.00K368.00K349.00K350.00K390.00K451.00K338.00K270.00K248.00K476.00K-85.00K33.00K84.00K10.00K26.00K206.00K200.00K0325.00K536.00K601.00K470.00K506.00K427.00K-594.00K575.00K557.00K-

Profit & Loss (Annual)

Figures in USD.

Metric Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 9.75M12.74M15.45M13.67M13.85M9.37M12.82M16.66M18.97M17.93M18.63M-13.27M12.73M14.29M19.53M
Cost of Revenue ------------8.79M7.99M8.82M12.11M
Gross Profit 6.14M8.71M10.74M8.40M7.29M2.65M5.67M7.31M8.88M8.12M6.56M-4.48M4.75M5.46M7.42M
Operating Expenses ------------9.05M9.45M9.18M9.88M
Operating Income -7.50M-6.47M-3.37M-6.05M-6.66M-14.71M-12.97M-14.19M-11.26M-7.39M-3.45M--4.57M-4.70M-3.71M-2.46M
EBITDA -------------4.45M-4.53M-3.57M-2.32M
Interest Expense ----------------
Pretax Income -------------5.18M-5.03M-2.91M-3.42M
Tax Provision -------------33.00K-196.00K550.00K-244.00K
Net Income -7.95M-7.33M-5.43M3.73M-8.20M-10.16M9.27M-14.33M-11.80M-3.31M-3.95M--5.15M-4.83M-3.46M-3.17M
Diluted EPS ---1.300.54-0.85--------30.40-10.63-2.79-1.89
R&D Expense 2.05M1.98M2.22M2.89M1.53M1.81M1.58M1.57M1.52M1.34M555.00K125.00K207.00K1.87M1.81M2.27M

Balance Sheet (Annual)

Figures in USD.

Metric Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -8.66M7.84M12.56M20.79M15.05M13.80M25.46M19.21M14.45M14.56M14.99M-16.23M14.74M13.69M13.96M
Current Assets -------------13.80M12.55M12.65M12.10M
Cash & Equivalents 6.26M4.37M3.35M7.90M5.48M6.14M7.47M17.46M10.07M3.69M3.69M4.22M-3.82M3.13M5.37M2.40M
Inventory -------------2.86M2.72M2.92M3.65M
Receivables -------------2.57M2.90M2.23M2.53M
Total Liabilities -6.96M8.71M8.48M8.73M2.99M3.66M4.03M3.88M3.96M8.94M9.62M-8.25M8.60M9.28M10.87M
Current Liabilities -4.42M4.75M5.13M7.57M2.58M3.55M3.29M3.26M3.59M4.73M4.08M-3.72M3.72M4.10M4.83M
Long Term Debt -1.64M1.82M676.00K4.00K0045.00K32.00K12.00K01.31M-----
Total Debt -------------849.00K608.00K305.00K842.00K
Total Equity 7.04M1.70M-868.00K4.08M12.06M12.05M10.14M21.43M15.33M7.77M5.62M5.36M-7.98M6.14M4.41M3.10M
Shares Outstanding -------------246.68K780.37K1.63M1.80M

Cash Flows (Annual)

Figures in USD.

Metric Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -4.43M-4.03M1.15M------11.72M-4.59M-3.38M--6.15M-2.40M-88.00K-3.93M
Investing Cash Flow -164.00K-360.00K-370.00K------131.00K3.64M388.00K--258.00K-2.00K-80.00K-192.00K
Financing Cash Flow 2.68M3.45M3.75M-----5.49M1.03M3.31M-2.49M1.68M3.03M477.00K
Capital Expenditure -174.00K-336.00K-257.00K-504.00K-139.00K-345.00K-394.00K-187.00K-100.00K-206.00K-179.00K--269.00K-2.00K-80.00K-192.00K
Free Cash Flow -4.60M-4.37M893.00K------11.82M-4.80M-3.56M--6.42M-2.40M-168.00K-4.12M
Net Change in Cash -------------3.92M-724.00K2.86M-3.65M

Ratios (Annual)

Figures in %.

Metric Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % 63.0%68.4%69.5%61.4%52.6%28.3%44.2%43.9%46.8%45.3%35.2%-33.7%37.3%38.2%38.0%
Operating Margin % -76.9%-50.7%-21.8%-44.3%-48.1%-157.0%-101.2%-85.2%-59.3%-41.2%-18.5%--34.4%-36.9%-26.0%-12.6%
Net Margin % -81.5%-57.5%-35.1%27.3%-59.2%-108.5%72.3%-86.0%-62.2%-18.5%-21.2%--38.8%-38.0%-24.2%-16.3%
ROE % -467.3%844.4%-133.1%31.0%-68.1%-100.2%43.3%-93.5%-151.8%-58.8%-73.7%--64.6%-78.8%-78.4%-102.6%
ROCE % -176.6%-209.4%-45.4%-45.8%-53.4%-143.5%-58.5%-89.0%-103.7%-75.2%-31.6%--36.5%-42.7%-38.7%-27.0%

Shareholding Pattern

Insiders
0.42%
Institutions
2.31%
Public Float
2.32%

Top Institutional Holders

#Holder% HeldSharesValue
1 Renaissance Technologies, LLC 0.85% 40.47K $51.80K
2 Geode Capital Management, LLC 0.56% 26.79K $34.29K
3 Vanguard Capital Management LLC 0.39% 18.79K $24.05K
4 McKinley Carter Wealth Services, Inc. 0.23% 11.19K $14.33K
5 UBS Group AG 0.16% 7.81K $9.99K
6 Global Retirement Partners, LLC 0.05% 2.55K $3.26K
7 Morgan Stanley 0.04% 2.00K $2.56K
8 Osaic Holdings Inc. 0.01% 500 $639
9 Barclays Plc 0.01% 459 $587
10 Blackrock Inc. - 113 $144

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SNOA

Google News Sat, 05 Sep 2026

Sonoma Pharmaceuticals Stock Price Forecast. Should You Buy SNOA? - StockInvest.us

<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE1NV0RadTdfVUM1Z3pPR1hsVHNZeFM4TWZxdWRQc2k5dFpQWkdxMjJhdmdWWldTd2xXUzlIdFg1eEdXNVQ4UzFkbw?oc=5" target="_blank">Sonoma Pharmaceuticals Stock Price Forecast. Should You Buy SNOA?</a>…

Google News hu, 28 May 2026

SNOA - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5VaHJLMnlVVTlQUzFxcjVTV29sYzRFdTA2WU9TUV95OXhEQVpWNUwyQmlhVjQ0WFh6UDJ0SGJEWWdXak9ZM3c?oc=5" target="_blank">SNOA</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

Google News Wed, 14 Jan 2026

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Could Be Riskier Than It Looks - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxPQkRpdXlyLTZBN1E2NlU5UnNOWHN3MnFWSVQzTUo5bTBkdWZSek9fdTk5SktxcEpwd3ZKRDU5N0RKN25YVjZBWkFvWkU4RGVWZ0x0SDZBQWJkSUpTMXZSS242YUJiTDJtSFE3eHRaMTFobTFabWtXRjhJS3JKNkE2ZjhCd2lDWjIydklucG…

Google News Sun, 26 Apr 2026

SNOA Drops As Sonoma Pharmaceuticals Launches Dilutive Offering - StocksToTrade

<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxOSlZiVWxMaW44cUtuQnlyekc2eVlOTnM3cUlrZmVUS01JYXRDc2tyNkpzcnI2eFFmOWRNTDd1TTN5aUhQdl9hbk16dy1haXZCVmNnbGxpc0tUUDZGc0I0ZHVTMWhMUEo1LV9CbkxTbDJKNWNiVGhDa3lBY3EyNHZ4QVNpQQ?oc=5" targe…

Google News Sat, 22 Aug 2026

Sonoma (SNOA) Shares: Holds Near $1.34 at the Close; Technical View: the Session Ends Within the Reported Technical Boundaries in Latest Trading - Bear Flag - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMijAJBVV95cUxPaWYtaWJWaUNMbUdJZGN4RHlwTXhXZkQzWHhqV3NBUHRlNUtweEM4eEthakgtcmo2ZjNYdGFNODhYQWNKLVQzbE5wakdHWUN3Z1U0dGROYVZ4LWtMSVRwdEFXdkZwV2dWSDVSMWFNaUJTd2sweVUyOWgzYVF1bmNVeV80c0poc0lLZ050OG…

Google News Sat, 22 Aug 2026

Sonoma (SNOA) Shares: Holds Near $1.34 at the Close; Technical View: the Session Ends Within the Reported Technical Boundaries in Latest Trading - Demand Zone - dars.gov.et

<a href="https://news.google.com/rss/articles/CBMijwJBVV95cUxNWjMtMmtpcWtraURDaVU4VEduQW5XSDI5bFF4U0xxSTVIeVltMExTbVdvVVg2MVFHaXZGbUJSdTZOdEhfXzVkM1liYldLOUpmRzZTbFZNS2tuQUt2QmtaOXlodzVEcUhWaUVDV2JIb242X0J0bVJjNWNOTzh3RmtFdml6Vzd0OVl3cjZVYn…

SNOA — Frequently Asked Questions

What is the current share price of Sonoma Pharmaceuticals, Inc. (SNOA)?

As of 2026-09-19 21:16 PDT, Sonoma Pharmaceuticals, Inc. (SNOA) trades at $1.33 on NasdaqCM. Its 52-week range is $1.01 to $5.35.

What is the market capitalisation of SNOA?

Sonoma Pharmaceuticals, Inc. (SNOA) has a market capitalisation of $6.37M on NasdaqCM.

What is the P/E ratio of SNOA?

SNOA trades at a trailing price-to-earnings (P/E) ratio of -1.09. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.74.

What is the return on equity (ROE) of SNOA?

SNOA has a return on equity (ROE) of -42.52%. Its return on capital employed (ROCE) is -26.96%.

Is SNOA a good stock to buy?

This page provides a data-driven analysis of Sonoma Pharmaceuticals, Inc. (SNOA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space